The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Carbamazepine for acute and chronic pain in adults
Open accessAbstract
BACKGROUND: Carbamazepine is used to treat chronic neuropathic pain. OBJECTIVES: Evaluation of analgesic efficacy and adverse effects of carbamazepine for acute and chronic pain management (except headaches). SEARCH STRATEGY: Randomised controlled trials (RCTs) of carbamazepine in acute, chronic or cancer pain were identified, searching MEDLINE, EMBASE, SIGLE and Cochrane CENTRAL to June 2010, reference lists of retrieved papers, and reviews. SELECTION CRITERIA: RCTs reporting the analgesic effects of carbamazepine. DATA COLLECTION AND ANALYSIS: Two authors independently extracted results and scored for quality. Numbers needed to treat to benefit (NNT) or harm (NNH) with 95% confidence intervals (CI) were calculated from dichotomous data for effectiveness, adverse effects and adverse event withdrawal. Issues of study quality, size, duration, and outcomes were examined. MAIN RESULTS: Fifteen included studies (12 cross-over design; three parallel-group) with 629 participants.Carbamazepine was less effective than prednisolone in preventing postherpetic neuralgia following acute herpes zoster (1 study, 40 participants). No studies examined acute postoperative pain.Fourteen studies investigated chronic neuropathic pain: two lasted eight weeks, others were four weeks or less (mean 3 weeks, median 2 weeks). Five had low reporting quality. Ten involved fewer than 50 participants; mean and median maximum treatment group sizes were 34 and 29. Outcome reporting was inconsistent.Most placebo controlled studies indicated that carbamazepine was better than placebo. Five studies with 298 participants provided dichotomous results; 70% improved with carbamazepine and 12% with placebo. Carbamazepine at any dose, using any definition of improvement was significantly better than placebo (70% versus 12% improved; 5 studies, 298 participants); relative benefit 6.1 (3.9 to 9.7), NNT 1.7 (1.5 to 2.0). Four studies (188 participants) reporting outcomes equivalent to 50% pain reduction or more over baseline had a similar NNT.With carbamazepine, 66% of participants experienced at least one adverse event, and 27% with placebo; relative risk 2.4 (1.9 to 3.1), NNH 2.6 (2.1 to 3.5). Adverse event withdrawals occurred in12 of 323 participants (4%) with carbamazepine and 0 of 310 with placebo. Serious adverse events were not reported consistently; rashes were associated with carbamazepine. Five deaths occurred in patients on carbamazepine, with no obvious drug association. AUTHORS' CONCLUSIONS: Carbamazepine is effective in chronic neuropathic pain, with caveats. No trial was longer than four weeks, of good reporting quality, using outcomes equivalent to at least moderate clinical benefit. In these circumstances, caution is needed in interpretation, and meaningful comparison with other interventions is not possible.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dworkin, R. H., Turk, D. C., Wyrwich, K. W., Beaton, D., Cleeland, C. S., Farrar, J. T., Haythornthwaite, J. A., Jensen, M. P., Kerns, R. D., Ader, D. N., et al. (2008) · The Journal of Pain · doi:10.1016/j.jpain.2007.09.005 · Cited by 3,471
Self-citationMeta-analyses involving cross-over trials: methodological issues
Elbourne, D. R., Altman, D. G., Higgins, J. P., Curtin, F., Worthington, H. V., & Vail, A. (2002) · International Journal of Epidemiology · doi:10.1093/ije/31.1.140 · Cited by 2,305
The number needed to treat: a clinically useful measure of treatment effect
Cook, R. J., & Sackett, D. L. (1995) · BMJ · doi:10.1136/bmj.310.6977.452 · Cited by 1,885
How neuroimaging studies have challenged us to rethink: Is chronic pain a disease?
Tracey, I., & Bushnell, M. C. (2009) · The Journal of Pain · doi:10.1016/j.jpain.2009.09.001 · Cited by 455
Moore, R. A., Moore, O. A., Derry, S., Peloso, P. M., Gammaitoni, A. R., & Wang, H. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2009.107805 · Cited by 279
Self-citationMoore, R. A., Derry, S., McQuay, H. J., Straube, S., Aldington, D., Wiffen, P., Bell, R. F., Kalso, E., & Rowbotham, M. C. (2010) · Pain · doi:10.1016/j.pain.2009.08.007 · Cited by 98
Self-citation
Cited by
Gabapentin for chronic neuropathic pain and fibromyalgia in adults
Moore, R. A., Wiffen, P. J., Derry, S., & McQuay, H. J. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007938.pub2 · Cited by 690
Self-citationTrigeminal neuralgia – diagnosis and treatment
Maarbjerg, S., Di Stefano, G., Bendtsen, L., & Cruccu, G. (2017) · Cephalalgia · doi:10.1177/0333102416687280 · Cited by 558
Trigeminal neuralgia: An overview from pathophysiology to pharmacological treatments
Gambeta, E., Chichorro, J. G., & Zamponi, G. W. (2020) · Molecular Pain · doi:10.1177/1744806920901890 · Cited by 376
Neurological perspectives on voltage-gated sodium channels
Eijkelkamp, N., Linley, J. E., Baker, M. D., Minett, M. S., Cregg, R., Werdehausen, R., Rugiero, F., & Wood, J. N. (2012) · Brain · doi:10.1093/brain/aws225 · Cited by 359
Antiepileptic drugs for neuropathic pain and fibromyalgia - an overview of Cochrane reviews
Wiffen, P. J., Derry, S., Moore, R. A., Aldington, D., Cole, P., Rice, A. S., Lunn, M. P., Hamunen, K., Haanpaa, M., & Kalso, E. A. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010567.pub2 · Cited by 306
Self-citationValproic acid and sodium valproate for neuropathic pain and fibromyalgia in adults
Gill, D., Derry, S., Wiffen, P. J., & Moore, R. A. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009183.pub2 · Cited by 253
Self-citationO'Connell, N. E., Wand, B. M., McAuley, J. H., Marston, L., & Moseley, G. L. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009416.pub2 · Cited by 244
Herpes Zoster: Diagnostic, Therapeutic, and Preventive Approaches
Bader, M. S. (2013) · Postgraduate Medicine · doi:10.3810/pgm.2013.09.2703 · Cited by 90
Metadata
- Authors
- Wiffen, P. J., Derry, S., Moore, R. A., & McQuay, H. J.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- John Wiley & Sons, Ltd
- Published
- 2011-01-19
- Issue
- 1
- Pages
- CD005451-CD005451
- ISSN
- 1361-6137 (ISSN-L)
- OpenAlex
- W2156033130
- Cited by
- 178
- References
- 6
- Type
- reference entry
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.